Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Astrotech Corporation (ASTC) 13.03 + 9.16%
After hours: 13.48 +0.45 (+3.43%)
today high: 14.0738
https://www.astrotechcorp.com/_files/ugd/bac33b_384cbca1154e48d1a4093af8a8c2e442.pdf
Year-to-date gross margin increased to 38% from 18%, an increase of 111%, for fiscal year 2023, compared to fiscal year 2022, due to the higher margins provided by recurring maintenance services and consumables sales.
Astrotech’s Board of Directors authorized a $1 million dollar share repurchase program, effective November 17, 2022.
Shares Outstanding 1.69M
Float 1.29M
Total Cash (mrq) 48.95M
Total Cash Per Share (mrq) 28.95
Total Debt (mrq) 480k
Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology. The company also develops TRACER 1000, a mass spectrometer-based explosive trace detector to replace the explosives trace detectors used at airports, cargo and other secured facilities, and borders. In addition, it develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. Further, the company develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 and is based in Austin, Texas.
TIme for a strong rebound:
Dec 01, 2022 9.90 11.82 9.28 9.99 9.99 546,417
Oct 31, 2022 12.00 13.50 9.30 10.20 10.20 301,281
Sep 30, 2022 13.20 13.80 10.20 12.30 12.30 183,265
Aug 31, 2022 13.80 14.40 12.30 13.20 13.20 204,439
Jul 31, 2022 13.80 16.20 12.30 13.80 13.80 263,144
Jun 30, 2022 12.60 14.70 12.60 13.80 13.80 63,550
May 31, 2022 16.50 17.10 12.60 12.90 12.90 107,050
Apr 30, 2022 15.90 16.80 14.40 16.50 16.50 98,090
Mar 31, 2022 21.60 22.20 15.90 16.20 16.20 121,183
Mar 01, 2022 21.60 23.10 19.80 21.60 21.60 192,625
Feb 01, 2022 19.20 22.20 18.00 21.30 21.30 249,151
Jan 01, 2022 20.40 23.10 18.00 19.50 19.50 234,297
Dec 01, 2021 24.30 24.60 19.50 20.40 20.40 371,402
Oct 31, 2021 31.20 33.00 22.80 24.00 24.00 522,731
Sep 30, 2021 31.50 34.50 29.10 30.90 30.90 726,944
Aug 31, 2021 33.30 33.90 28.80 31.50 31.50 391,866
Jul 31, 2021 34.50 36.30 28.20 33.30 33.30 1,657,386
Jun 30, 2021 41.40 42.00 30.00 32.40 32.40 963,596
May 31, 2021 35.40 39.90 33.60 39.90 39.90 1,113,366
Apr 30, 2021 36.90 37.20 30.90 35.10 35.10 998,583
Mar 31, 2021 66.60 89.40 32.10 36.90 36.90 6,113,055
Mar 01, 2021 70.50 76.20 42.90 65.70 65.70 1,323,382
Feb 01, 2021 59.40 124.20 59.40 65.70 65.70 2,390,276
Jan 01, 2021 53.10 79.50 51.90 61.20 61.20 924,834
Dec 01, 2020 58.50 63.30 50.40 53.10 53.10 537,875
Oct 31, 2020 58.50 59.70 47.40 58.50 58.50 498,903
Sep 30, 2020 51.90 184.20 46.80 59.70 59.70 6,190,508
Aug 31, 2020 64.50 76.50 43.20 51.00 51.00 1,010,051
Jul 31, 2020 92.40 108.90 63.30 65.70 65.70 140,379
Jun 30, 2020 86.10 110.10 76.20 92.40 92.40 305,287
May 31, 2020 78.90 101.10 76.80 85.50 85.50 207,531
Apr 30, 2020 90.00 109.80 76.50 80.40 80.40 263,573
Mar 31, 2020 73.20 126.00 65.40 89.10 89.10 624,170
Mar 01, 2020 49.80 232.50 29.40 78.00 78.00 2,294,158
WNBD: 0.0002
0.0002 - 0.0013
https://www.winningbrandscorporation.com/index.html
Winning Brands Unveiling More GestureTek Technology at Emerging Growth Conference
WNBD Profit Through Service to the Medical Market is the Focus of the Interactive Videocast
TORONTO, ON / ACCESSWIRE / February 21, 2023 / Winning Brands Corporation (OTC PINK:WNBD) expands its Video Communications Schedule for WNBD shareholders with a further video briefing on Wednesday, February 22nd at 3:10pm Eastern Time, to discuss medical market profit opportunities.
Management personnel of Winning Brands' new tech division, GestureTek Media, will present more information in collaboration with the Emerging Growth Conference organization. The videocast on February 22nd will focus on the significant profit opportunity for WNBD of service to patients and medical practitioners with GestureTek technology; www.GestureTekHealth.com. A special link to register and participate in the videocast follows: https://goto.webcasts.com/starthere.jsp?ei=1595541&tp_key=7d6588b9a9&sti=wnbd
The rapid pace of GestureTek's video interactions with Winning Brands shareholders illustrates to WNBD shareholders the high energy of Winning Brands' embrace of tech sector operations.
GestureTek is the inventor and early developer of the hot tech sector that aims to control digital displays and devices through hand and body movements. GestureTek's technology has been at the leading edge of innovation in touchless immersive gesture control of a wide array of visual display systems, across diverse industries. The GestureTek brand is well known and respected in this market, and enjoys a large installed commercial customer base worldwide. A brief overview of GestureTek's award-winning history in medical and other sectors can be seen in its websites or found in any internet search with the search term "GestureTek". Company websites include: www.GestureTek.com and www.GestureTekHealth.com. These digital assets will be updated in coming months to reflect corporate developments. Abundant video resources are also available at https://vimeo.com/search?q=GestureTek. GestureTek is now a division of Winning Brands (OTC:WNBD)
Winning Brands Corp., Tuesday, February 21, 2023, Press release picture
Winning Brands Corp., Tuesday, February 21, 2023, Press release picture
ABOUT WINNING BRANDS CORPORATION
Winning Brands has been a manufacturer of record of a variety of environmentally oriented consumer chemical products. Winning Brands indicated in its public communications that it seeks to enhance shareholder value by curating additional business ventures with broader scope, including the launch of a Tech Division. This Tech Division is the new home of the GestureTek brand.
ABOUT THE EMERGING GROWTH CONFERENCE
The Emerging Growth conference is a preferred method for public companies to present and discuss their new products, services and other major announcements to the investment community. The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its aggregate audience includes tens of thousands of individual and institutional investors, as well as investment advisors and analysts. All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
WNBD: 0.0002
0.0002 - 0.0013
https://www.winningbrandscorporation.com/index.html
Winning Brands Unveiling More GestureTek Technology at Emerging Growth Conference
WNBD Profit Through Service to the Medical Market is the Focus of the Interactive Videocast
TORONTO, ON / ACCESSWIRE / February 21, 2023 / Winning Brands Corporation (OTC PINK:WNBD) expands its Video Communications Schedule for WNBD shareholders with a further video briefing on Wednesday, February 22nd at 3:10pm Eastern Time, to discuss medical market profit opportunities.
Management personnel of Winning Brands' new tech division, GestureTek Media, will present more information in collaboration with the Emerging Growth Conference organization. The videocast on February 22nd will focus on the significant profit opportunity for WNBD of service to patients and medical practitioners with GestureTek technology; www.GestureTekHealth.com. A special link to register and participate in the videocast follows: https://goto.webcasts.com/starthere.jsp?ei=1595541&tp_key=7d6588b9a9&sti=wnbd
The rapid pace of GestureTek's video interactions with Winning Brands shareholders illustrates to WNBD shareholders the high energy of Winning Brands' embrace of tech sector operations.
GestureTek is the inventor and early developer of the hot tech sector that aims to control digital displays and devices through hand and body movements. GestureTek's technology has been at the leading edge of innovation in touchless immersive gesture control of a wide array of visual display systems, across diverse industries. The GestureTek brand is well known and respected in this market, and enjoys a large installed commercial customer base worldwide. A brief overview of GestureTek's award-winning history in medical and other sectors can be seen in its websites or found in any internet search with the search term "GestureTek". Company websites include: www.GestureTek.com and www.GestureTekHealth.com. These digital assets will be updated in coming months to reflect corporate developments. Abundant video resources are also available at https://vimeo.com/search?q=GestureTek. GestureTek is now a division of Winning Brands (OTC:WNBD)
Winning Brands Corp., Tuesday, February 21, 2023, Press release picture
Winning Brands Corp., Tuesday, February 21, 2023, Press release picture
ABOUT WINNING BRANDS CORPORATION
Winning Brands has been a manufacturer of record of a variety of environmentally oriented consumer chemical products. Winning Brands indicated in its public communications that it seeks to enhance shareholder value by curating additional business ventures with broader scope, including the launch of a Tech Division. This Tech Division is the new home of the GestureTek brand.
ABOUT THE EMERGING GROWTH CONFERENCE
The Emerging Growth conference is a preferred method for public companies to present and discuss their new products, services and other major announcements to the investment community. The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its aggregate audience includes tens of thousands of individual and institutional investors, as well as investment advisors and analysts. All sessions will be conducted through video webcasts and will take place in the Eastern time zone.
ReShape Lifesciences Inc. (RSLS) : 4.3700+0.3000 (+7.37%)
52 Week Range 3.8300 - 77.0000
big news after hours:
MATTHEW NACHTRAB REPORTS 27.7% STAKE IN RESHAPE LIFESCIENCES AS
NACHTRAB-PURCHASED CO'S COMMON STOCK BASED ON BELIEF THAT SUCH SECURITIES, AT CURRENT MARKET PRICES, REPRESENTED AN ATTRACTIVE INVESTMENT OPPORTUNITY
NACHTRAB - WROTE A LETTER TO THE CEO OF CO WITH RECOMMENDATIONS FOR THE MANAGEMENT TEAM’S STRATEGY GOING FORWARD
https://www.sec.gov/Archives/edgar/data/897069/000089706923000114/reshapenatrab13d.htm
I am excited for your new tenure as CEO of ReShape Lifesciences and I believe your team can rebuild and create a $100m plus market cap company with some austerity measures, leveraging assets currently owned, and capitalizing on the medicated weight loss secular trend to generate lead flow and massive revenue growth. I am willing to discuss this and advise in any way I can help.
Feb 15, 2023 4.0500 4.5000 3.8300 4.3700 4.3700 889,315
Feb 14, 2023 4.4400 4.4400 3.9100 4.0700 4.0700 379,100
Feb 13, 2023 4.9000 4.9000 4.2500 4.3300 4.3300 568,800
Feb 10, 2023 5.3300 5.4500 5.0000 5.0200 5.0200 519,700
Feb 09, 2023 5.8700 5.9200 5.3800 5.5300 5.5300 715,000
Feb 08, 2023 6.2000 8.2000 5.5700 5.9050 5.9050 5,910,000
Feb 07, 2023 6.6500 6.7280 6.0600 6.1600 6.1600 931,200
Feb 06, 2023 6.5000 7.4500 6.3500 6.9500 6.9500 5,427,300
Feb 03, 2023 13.1400 22.4000 11.5600 17.0400 17.0400 11,599,000
Feb 02, 2023 6.6300 6.7000 6.0600 6.3000 6.3000 708,000
Feb 01, 2023 7.1100 7.3300 6.5500 6.5600 6.5600 54,000
Jan 31, 2023 7.4100 7.5800 6.8600 7.2400 7.2400 176,500
Jan 30, 2023 8.1400 8.1400 7.5200 7.8000 7.8000 16,400
Jan 27, 2023 8.4100 8.4100 7.6500 7.8700 7.8700 32,400
Jan 26, 2023 7.6400 8.4060 7.6000 8.1700 8.1700 44,600
Jan 25, 2023 7.4100 7.7500 7.3700 7.5600 7.5600 31,400
Jan 24, 2023 7.4900 7.7500 7.4000 7.5700 7.5700 29,500
Jan 23, 2023 7.5400 7.7500 7.3900 7.6700 7.6700 27,600
Jan 20, 2023 7.1800 7.7500 7.1100 7.6800 7.6800 14,900
Jan 19, 2023 7.2200 7.4800 7.2000 7.2000 7.2000 8,900
Jan 18, 2023 8.1700 8.3200 7.2900 7.3000 7.3000 29,300
Jan 17, 2023 8.3800 8.5400 7.8200 8.0500 8.0500 40,000
Jan 13, 2023 7.8100 9.1100 7.8100 8.7200 8.7200 105,300
Jan 12, 2023 7.6100 8.2000 7.6100 7.9500 7.9500 23,300
Jan 11, 2023 7.5800 8.1800 7.5800 8.0100 8.0100 38,900
Jan 10, 2023 7.4200 8.2760 7.1800 7.8100 7.8100 115,600
Jan 09, 2023 7.5100 7.6700 7.2700 7.5600 7.5600 75,100
Jan 06, 2023 7.1500 8.1700 7.0800 7.2600 7.2600 152,000
Jan 05, 2023 9.0600 9.0600 7.2600 7.5300 7.5300 211,900
Jan 04, 2023 12.3300 13.4500 8.9000 8.9000 8.9000 886,800
Jan 03, 2023 9.6600 20.6300 9.4500 15.6600 15.6600 12,363,900
ReShape Lifesciences Inc. (RSLS) : 4.3700+0.3000 (+7.37%)
52 Week Range 3.8300 - 77.0000
big news after hours:
MATTHEW NACHTRAB REPORTS 27.7% STAKE IN RESHAPE LIFESCIENCES AS
NACHTRAB-PURCHASED CO'S COMMON STOCK BASED ON BELIEF THAT SUCH SECURITIES, AT CURRENT MARKET PRICES, REPRESENTED AN ATTRACTIVE INVESTMENT OPPORTUNITY
NACHTRAB - WROTE A LETTER TO THE CEO OF CO WITH RECOMMENDATIONS FOR THE MANAGEMENT TEAM’S STRATEGY GOING FORWARD
https://www.sec.gov/Archives/edgar/data/897069/000089706923000114/reshapenatrab13d.htm
I am excited for your new tenure as CEO of ReShape Lifesciences and I believe your team can rebuild and create a $100m plus market cap company with some austerity measures, leveraging assets currently owned, and capitalizing on the medicated weight loss secular trend to generate lead flow and massive revenue growth. I am willing to discuss this and advise in any way I can help.
Feb 15, 2023 4.0500 4.5000 3.8300 4.3700 4.3700 889,315
Feb 14, 2023 4.4400 4.4400 3.9100 4.0700 4.0700 379,100
Feb 13, 2023 4.9000 4.9000 4.2500 4.3300 4.3300 568,800
Feb 10, 2023 5.3300 5.4500 5.0000 5.0200 5.0200 519,700
Feb 09, 2023 5.8700 5.9200 5.3800 5.5300 5.5300 715,000
Feb 08, 2023 6.2000 8.2000 5.5700 5.9050 5.9050 5,910,000
Feb 07, 2023 6.6500 6.7280 6.0600 6.1600 6.1600 931,200
Feb 06, 2023 6.5000 7.4500 6.3500 6.9500 6.9500 5,427,300
Feb 03, 2023 13.1400 22.4000 11.5600 17.0400 17.0400 11,599,000
Feb 02, 2023 6.6300 6.7000 6.0600 6.3000 6.3000 708,000
Feb 01, 2023 7.1100 7.3300 6.5500 6.5600 6.5600 54,000
Jan 31, 2023 7.4100 7.5800 6.8600 7.2400 7.2400 176,500
Jan 30, 2023 8.1400 8.1400 7.5200 7.8000 7.8000 16,400
Jan 27, 2023 8.4100 8.4100 7.6500 7.8700 7.8700 32,400
Jan 26, 2023 7.6400 8.4060 7.6000 8.1700 8.1700 44,600
Jan 25, 2023 7.4100 7.7500 7.3700 7.5600 7.5600 31,400
Jan 24, 2023 7.4900 7.7500 7.4000 7.5700 7.5700 29,500
Jan 23, 2023 7.5400 7.7500 7.3900 7.6700 7.6700 27,600
Jan 20, 2023 7.1800 7.7500 7.1100 7.6800 7.6800 14,900
Jan 19, 2023 7.2200 7.4800 7.2000 7.2000 7.2000 8,900
Jan 18, 2023 8.1700 8.3200 7.2900 7.3000 7.3000 29,300
Jan 17, 2023 8.3800 8.5400 7.8200 8.0500 8.0500 40,000
Jan 13, 2023 7.8100 9.1100 7.8100 8.7200 8.7200 105,300
Jan 12, 2023 7.6100 8.2000 7.6100 7.9500 7.9500 23,300
Jan 11, 2023 7.5800 8.1800 7.5800 8.0100 8.0100 38,900
Jan 10, 2023 7.4200 8.2760 7.1800 7.8100 7.8100 115,600
Jan 09, 2023 7.5100 7.6700 7.2700 7.5600 7.5600 75,100
Jan 06, 2023 7.1500 8.1700 7.0800 7.2600 7.2600 152,000
Jan 05, 2023 9.0600 9.0600 7.2600 7.5300 7.5300 211,900
Jan 04, 2023 12.3300 13.4500 8.9000 8.9000 8.9000 886,800
Jan 03, 2023 9.6600 20.6300 9.4500 15.6600 15.6600 12,363,900
Time for a strong rebound?
Trevena, Inc. (TRVN): 1.2400-0.0500 (-3.88%)
52 Week Range 1.1200 - 15.2750
Total Cash (mrq) 40.39M
Total Cash Per Share (mrq) 5.81
Shares Outstanding 7.71M
Float 6.86M
Trading 4x+ below cash on hand as of Q3 end. So much manipulation and games being played.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
last month
Feb 13, 2023 1.2800 1.3000 1.1200 1.1800 1.1800 55,267
Feb 10, 2023 1.3000 1.3100 1.2600 1.2900 1.2900 51,200
Feb 09, 2023 1.4300 1.4400 1.2600 1.3000 1.3000 207,700
Feb 08, 2023 1.4500 1.5100 1.4100 1.4400 1.4400 48,600
Feb 07, 2023 1.5100 1.5500 1.4000 1.4800 1.4800 79,700
Feb 06, 2023 1.5800 1.6200 1.4600 1.5100 1.5100 137,300
Feb 03, 2023 1.6800 1.7300 1.5400 1.5800 1.5800 241,900
Feb 02, 2023 1.7000 1.7600 1.6500 1.6800 1.6800 75,100
Feb 01, 2023 1.6750 1.7200 1.6000 1.6900 1.6900 54,500
Jan 31, 2023 1.7000 1.7300 1.6200 1.6500 1.6500 75,500
Jan 30, 2023 1.7100 1.7400 1.6400 1.6900 1.6900 42,100
Jan 27, 2023 1.7000 1.7820 1.6400 1.7100 1.7100 103,500
Jan 26, 2023 1.8100 1.8220 1.6100 1.7300 1.7300 92,200
Jan 25, 2023 1.8200 1.8500 1.7500 1.8100 1.8100 36,200
Jan 24, 2023 1.8800 1.9400 1.7500 1.8300 1.8300 60,700
Jan 23, 2023 1.9300 2.0300 1.8700 1.9000 1.9000 78,400
Jan 20, 2023 1.8300 1.9370 1.8200 1.8800 1.8800 38,800
Jan 19, 2023 2.0000 2.0000 1.8000 1.8600 1.8600 42,700
Jan 18, 2023 2.1300 2.2000 1.9100 1.9700 1.9700 83,600
Jan 17, 2023 2.0900 2.3100 2.0000 2.1600 2.1600 127,300
Time for a strong rebound?
Trevena, Inc. (TRVN): 1.2400-0.0500 (-3.88%)
52 Week Range 1.1200 - 15.2750
Total Cash (mrq) 40.39M
Total Cash Per Share (mrq) 5.81
Shares Outstanding 7.71M
Float 6.86M
Trading 4x+ below cash on hand as of Q3 end. So much manipulation and games being played.
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
last month
Feb 13, 2023 1.2800 1.3000 1.1200 1.1800 1.1800 55,267
Feb 10, 2023 1.3000 1.3100 1.2600 1.2900 1.2900 51,200
Feb 09, 2023 1.4300 1.4400 1.2600 1.3000 1.3000 207,700
Feb 08, 2023 1.4500 1.5100 1.4100 1.4400 1.4400 48,600
Feb 07, 2023 1.5100 1.5500 1.4000 1.4800 1.4800 79,700
Feb 06, 2023 1.5800 1.6200 1.4600 1.5100 1.5100 137,300
Feb 03, 2023 1.6800 1.7300 1.5400 1.5800 1.5800 241,900
Feb 02, 2023 1.7000 1.7600 1.6500 1.6800 1.6800 75,100
Feb 01, 2023 1.6750 1.7200 1.6000 1.6900 1.6900 54,500
Jan 31, 2023 1.7000 1.7300 1.6200 1.6500 1.6500 75,500
Jan 30, 2023 1.7100 1.7400 1.6400 1.6900 1.6900 42,100
Jan 27, 2023 1.7000 1.7820 1.6400 1.7100 1.7100 103,500
Jan 26, 2023 1.8100 1.8220 1.6100 1.7300 1.7300 92,200
Jan 25, 2023 1.8200 1.8500 1.7500 1.8100 1.8100 36,200
Jan 24, 2023 1.8800 1.9400 1.7500 1.8300 1.8300 60,700
Jan 23, 2023 1.9300 2.0300 1.8700 1.9000 1.9000 78,400
Jan 20, 2023 1.8300 1.9370 1.8200 1.8800 1.8800 38,800
Jan 19, 2023 2.0000 2.0000 1.8000 1.8600 1.8600 42,700
Jan 18, 2023 2.1300 2.2000 1.9100 1.9700 1.9700 83,600
Jan 17, 2023 2.0900 2.3100 2.0000 2.1600 2.1600 127,300
Back to 5 today?
RSLS: 4,6587 -7,20%
Feb 03, 2023 : 22.4000
Back to 5 today?
RSLS: 4,6587 -7,20%
Feb 03, 2023 : 22.4000
Time for a strong recovery
RESHAPE LIFESCIENCES (RSLS): 4.4500-0.5700 (-11.35%)
Feb 13, 2023 5.3300 4.9000 4.2500 4.4500 4.4500 168,532
Feb 10, 2023 5.3300 5.4500 5.0000 5.0200 5.0200 519,700
Feb 09, 2023 5.8700 5.9200 5.3800 5.5300 5.5300 715,000
Feb 08, 2023 6.2000 8.2000 5.5700 5.9050 5.9050 5,910,000
Feb 07, 2023 6.6500 6.7280 6.0600 6.1600 6.1600 931,200
Feb 06, 2023 6.5000 7.4500 6.3500 6.9500 6.9500 5,427,300
Feb 03, 2023 13.1400 22.4000 11.5600 17.0400 17.0400 11,599,000
Total Cash (mrq) 16.35M = $9/share.
Total Debt (mrq) 255k
Shares Outstanding 1.79M
Float 478.54k
https://www.reshapelifesciences.com/
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
Time for a strong recovery
RESHAPE LIFESCIENCES (RSLS): 4.4500-0.5700 (-11.35%)
Feb 13, 2023 5.3300 4.9000 4.2500 4.4500 4.4500 168,532
Feb 10, 2023 5.3300 5.4500 5.0000 5.0200 5.0200 519,700
Feb 09, 2023 5.8700 5.9200 5.3800 5.5300 5.5300 715,000
Feb 08, 2023 6.2000 8.2000 5.5700 5.9050 5.9050 5,910,000
Feb 07, 2023 6.6500 6.7280 6.0600 6.1600 6.1600 931,200
Feb 06, 2023 6.5000 7.4500 6.3500 6.9500 6.9500 5,427,300
Feb 03, 2023 13.1400 22.4000 11.5600 17.0400 17.0400 11,599,000
Total Cash (mrq) 16.35M = $9/share.
Total Debt (mrq) 255k
Shares Outstanding 1.79M
Float 478.54k
https://www.reshapelifesciences.com/
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.
High volume!! and yes we are above the 2.50.
ONVO: 2,65 +36.11%
Volume 854,496
Avg. Volume 29,534
Shares Outstanding 8.71M
High volume!! and yes we are above the 2.50.
ONVO: 2,65 +36.11%
Volume 854,496
Avg. Volume 29,534
Shares Outstanding 8.71M
JAGX: 4.19
52: 4.16 - 61.49
Shares Outstanding 2.02M
Float 1.74M
woww
Jagx has a mktcap of 8.5M but they own:
Jaguar issued the below release this morning to announce the initial closing in a private placement financing round for Napo Therapeutics, the corporation we established in Italy in 2021. Jaguar currently owns approximately 73.5% of Napo Therapeutics, and this closing on funds was completed at a fully diluted valuation of approximately €55 million.”
This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million
Jaguar currently owns approximately 73.5% of Napo Therapeutics
Napo Therapeutics' mission is to provide access to Jaguar's proprietary first-in-class plant-based medicine crofelemer in Europe to address significant rare disease indications
SAN FRANCISCO, CA / February 9, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced a closing in a private placement financing round for Napo Therapeutics, the Italian corporation established by Jaguar in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe.
“As majority shareholders of Napo Therapeutics, we are very pleased with the closing of this initial investment which is part of a larger round of Napo Therapeutics funding expected to close before March 31, 2023. This initial investment, completed at a fully diluted valuation of approximately €55 million (including €8.8 million of exercise price of warrants issued), represents a step up from the first Napo Therapeutics funding round in December 2021 and is from SPRIM Global Investments, a prominent international venture capital firm focused on early-stage healthcare solutions that is associated with a clinical research organization (CRO). The CRO was able to benefit from its due diligence into Napo Therapeutics’ crofelemer development plan when evaluating and consummating this equity investment,” said Lisa Conte, Jaguar’s founder, president, and chief executive officer. “We are delighted that this investment broadens Napo Therapeutics’ investor base as we look forward to possible additional private placement financing rounds for Napo Therapeutics in addition to a possible future public listing of the company. We expect Napo Therapeutics to raise up to approximately €7 million in total as part of this current financing round, including additional participation from Jaguar.”
Napo Therapeutics’ mission is to provide access to Jaguar's proprietary first-in-class plant-based medicine crofelemer in Europe to address significant rare disease indications. The company's initial focus is on clinical development and future registration in Europe of crofelemer for two debilitating rare disease target indications: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) with intestinal failure. Crofelemer has received orphan drug designation from the European Medicines Agency (EMA) for both indications.
Napo Therapeutics intends to use the net proceeds from the current financing round to fund the company’s business activities, including supporting scientific and clinical requests from independent clinical investigators, engagement with key opinion leaders regarding the design of a pivotal trial of crofelemer, and scientific advice from the EMA related to clinical trial design.
The funds comprising the above-referenced initial closing in this private placement financing round for Napo Therapeutics are subject to a proportionate refund to the investor in the event that Napo Therapeutics reduces or cancels the service agreement it entered with the investor on December 29, 2022.
Structure of Financing Round
This financing round is structured as a private placement (i) in the U.S., to institutional “accredited investors” (as such term is defined in Rule 501 of Regulation D under the US Securities Act of 1933 (the “Securities Act”) and (ii) outside the U.S., to persons who are not U.S. persons (as defined in Regulation S under the Securities Act (“Regulation S”)) pursuant to Regulation S (“Eligible Investors”).
About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, & Napo Therapeutics
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com.
JAGX: 4.19
52: 4.16 - 61.49
Shares Outstanding 2.02M
Float 1.74M
woww
Jagx has a mktcap of 8.5M but they own:
Jaguar issued the below release this morning to announce the initial closing in a private placement financing round for Napo Therapeutics, the corporation we established in Italy in 2021. Jaguar currently owns approximately 73.5% of Napo Therapeutics, and this closing on funds was completed at a fully diluted valuation of approximately €55 million.”
This closing on funds from SPRIM Global Investments, a healthcare-focused international venture capital firm, was completed at a fully diluted valuation of approximately €55 million
Jaguar currently owns approximately 73.5% of Napo Therapeutics
Napo Therapeutics' mission is to provide access to Jaguar's proprietary first-in-class plant-based medicine crofelemer in Europe to address significant rare disease indications
SAN FRANCISCO, CA / February 9, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced a closing in a private placement financing round for Napo Therapeutics, the Italian corporation established by Jaguar in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe.
“As majority shareholders of Napo Therapeutics, we are very pleased with the closing of this initial investment which is part of a larger round of Napo Therapeutics funding expected to close before March 31, 2023. This initial investment, completed at a fully diluted valuation of approximately €55 million (including €8.8 million of exercise price of warrants issued), represents a step up from the first Napo Therapeutics funding round in December 2021 and is from SPRIM Global Investments, a prominent international venture capital firm focused on early-stage healthcare solutions that is associated with a clinical research organization (CRO). The CRO was able to benefit from its due diligence into Napo Therapeutics’ crofelemer development plan when evaluating and consummating this equity investment,” said Lisa Conte, Jaguar’s founder, president, and chief executive officer. “We are delighted that this investment broadens Napo Therapeutics’ investor base as we look forward to possible additional private placement financing rounds for Napo Therapeutics in addition to a possible future public listing of the company. We expect Napo Therapeutics to raise up to approximately €7 million in total as part of this current financing round, including additional participation from Jaguar.”
Napo Therapeutics’ mission is to provide access to Jaguar's proprietary first-in-class plant-based medicine crofelemer in Europe to address significant rare disease indications. The company's initial focus is on clinical development and future registration in Europe of crofelemer for two debilitating rare disease target indications: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) with intestinal failure. Crofelemer has received orphan drug designation from the European Medicines Agency (EMA) for both indications.
Napo Therapeutics intends to use the net proceeds from the current financing round to fund the company’s business activities, including supporting scientific and clinical requests from independent clinical investigators, engagement with key opinion leaders regarding the design of a pivotal trial of crofelemer, and scientific advice from the EMA related to clinical trial design.
The funds comprising the above-referenced initial closing in this private placement financing round for Napo Therapeutics are subject to a proportionate refund to the investor in the event that Napo Therapeutics reduces or cancels the service agreement it entered with the investor on December 29, 2022.
Structure of Financing Round
This financing round is structured as a private placement (i) in the U.S., to institutional “accredited investors” (as such term is defined in Rule 501 of Regulation D under the US Securities Act of 1933 (the “Securities Act”) and (ii) outside the U.S., to persons who are not U.S. persons (as defined in Regulation S under the Securities Act (“Regulation S”)) pursuant to Regulation S (“Eligible Investors”).
About Jaguar Health, Jaguar Animal Health, Napo Pharmaceuticals, & Napo Therapeutics
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, including chronic, debilitating diarrhea. Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human pharmaceuticals from plants harvested responsibly from rainforest areas. Our crofelemer drug product candidate is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Jaguar Health is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar Health in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe.
For more information about Jaguar Health, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo Therapeutics, visit napotherapeutics.com.
ONVO: Premarket: 2.25 + 0.31 (+15.95%)
Will we see 2.5 today???
Some think she's buying again: ARK Investment Management, run by the notable fund manager, Catherine Wood has disclosed a ~20.0% stake in Organovo Holdings (Feb. 17, 2021)
ONVO: Premarket: 2.25 + 0.31 (+15.95%)
Will we see 2.5 today???
Some think she's buying again: ARK Investment Management, run by the notable fund manager, Catherine Wood has disclosed a ~20.0% stake in Organovo Holdings (Feb. 17, 2021)
Organovo Holdings, Inc. (ONVO) :1.9400+0.2000 (+11.49%)
After hours: 2.1500 +0.21 (+10.82%)
Total Cash (mrq) 23.84M
Total Cash Per Share (mrq) 2.74
Total Debt (mrq) 2M
Shares Outstanding 8.71M
Nikko Asset Management Americas holds 461,376 shares representing 5.30% ownership of the company.
ARK Investment Management holds 214,302 shares representing 2.46% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 175,314 shares representing 2.01% ownership of the company.
ARKG - ARK Genomic Revolution ETF holds 174,266 shares representing 2.00% ownership of the company.
Renaissance Technologies holds 119,887 shares representing 1.38% ownership of the company.
Organovo Holdings, Inc. is an early stage biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). It uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.
Jan 01, 2023 1.4700 1.8900 1.4000 1.6300 1.6300 638,700
Mar 01, 2022 3.7300 4.6700 3.3400 3.7600 3.7600 1,061,400
Feb 01, 2021 12.7500 23.9200 11.0300 12.7500 12.7500 10,810,700
Jun 30, 2020 11.2000 17.4000 11.2000 13.2000 13.2000 1,603,005
Feb 01, 2019 20.2000 23.6000 19.0000 21.2000 21.2000 593,370
Apr 30, 2018 25.0000 41.8000 23.0000 39.4000 39.4000 1,589,720
Jan 01, 2017 70.8000 78.4000 67.0000 73.8000 73.8000 1,266,630
Jul 31, 2016 88.0000 99.8000 74.6000 77.2000 77.2000 1,330,340
Jan 01, 2015 143.2000 148.4000 120.2000 128.6000 128.6000 715,755
Jan 01, 2014 226.0000 247.6000 163.4000 189.0000 189.0000 5,330,400
Oct 31, 2013 150.0000 273.0000 132.2000 177.6000 177.6000 10,327,50
Organovo Holdings, Inc. (ONVO) :1.9400+0.2000 (+11.49%)
After hours: 2.1500 +0.21 (+10.82%)
Total Cash (mrq) 23.84M
Total Cash Per Share (mrq) 2.74
Total Debt (mrq) 2M
Shares Outstanding 8.71M
Nikko Asset Management Americas holds 461,376 shares representing 5.30% ownership of the company.
ARK Investment Management holds 214,302 shares representing 2.46% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 175,314 shares representing 2.01% ownership of the company.
ARKG - ARK Genomic Revolution ETF holds 174,266 shares representing 2.00% ownership of the company.
Renaissance Technologies holds 119,887 shares representing 1.38% ownership of the company.
Organovo Holdings, Inc. is an early stage biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). It uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted.
Jan 01, 2023 1.4700 1.8900 1.4000 1.6300 1.6300 638,700
Mar 01, 2022 3.7300 4.6700 3.3400 3.7600 3.7600 1,061,400
Feb 01, 2021 12.7500 23.9200 11.0300 12.7500 12.7500 10,810,700
Jun 30, 2020 11.2000 17.4000 11.2000 13.2000 13.2000 1,603,005
Feb 01, 2019 20.2000 23.6000 19.0000 21.2000 21.2000 593,370
Apr 30, 2018 25.0000 41.8000 23.0000 39.4000 39.4000 1,589,720
Jan 01, 2017 70.8000 78.4000 67.0000 73.8000 73.8000 1,266,630
Jul 31, 2016 88.0000 99.8000 74.6000 77.2000 77.2000 1,330,340
Jan 01, 2015 143.2000 148.4000 120.2000 128.6000 128.6000 715,755
Jan 01, 2014 226.0000 247.6000 163.4000 189.0000 189.0000 5,330,400
Oct 31, 2013 150.0000 273.0000 132.2000 177.6000 177.6000 10,327,50
Quince Therapeutics, Inc. (QNCX) : 1.0000-0.0800 (-7.41%)
Jan 30 (Reuters) - Quince Therapeutics Inc :
* QUINCE THERAPEUTICS - ON JANUARY 24, BOARD OF COMPANY
APPROVED
COST REDUCTION PROGRAM TO ALIGN OPERATIONS WITH CHANGES IN
CORPORATE STRATEGY
* QUINCE THERAPEUTICS - UNDER PLAN, COMPANY IS REDUCING
HEADCOUNT
BY APPROXIMATELY 47% THROUGH A REDUCTION IN ITS WORKFORCE
* QUINCE THERAPEUTICS - REDUCTION IN FORCE WILL BEGIN IN
FEBRUARY
2023 AND WILL BE COMPLETED BY APRIL 2023
* QUINCE THERAPEUTICS - AS A RESULT, EXPECTS TO REALIZE
ESTIMATED
ANNUALIZED OPERATING EXPENSE SAVINGS OF ABOUT $9.5 MILLION IN
YEAR ENDING DEC 31, 2023
* QUINCE THERAPEUTICS - REDUCTION IN FORCE WILL BEGIN IN
FEBRUARY
2023 AND WILL BE COMPLETED BY APRIL 2023
* QUINCE THERAPEUTICS - EXPECTS TO REALIZE ESTIMATED
ANNUALIZED
OPERATING EXPENSE SAVINGS OF APPROXIMATELY $9.5 MILLION IN YEAR
ENDING DECEMBER 31, 2023
* QUINCE THERAPEUTICS - IN CONNECTION WITH PLAN, COMPANY
ESTIMATES
THAT IT WILL INCUR EXPENSES OF APPROXIMATELY $0.6 MILLION TO
$0.8 MILLION
Jan 01, 2023 0.6450 1.4700 0.6370 1.0800 1.0800 67,051,000
Dec 01, 2022 0.7490 0.7600 0.5400 0.6370 0.6370 5,975,600
Oct 31, 2022 1.0000 1.0390 0.6500 0.7370 0.7370 5,404,500
Sep 30, 2022 1.3700 1.3700 0.8620 1.0000 1.0000 3,903,500
Aug 31, 2022 1.7300 1.7580 1.2000 1.3300 1.3300 4,722,200
Jul 31, 2022 1.9700 2.7170 1.6500 1.7600 1.7600 5,607,500
Jun 30, 2022 2.2700 2.5800 1.7820 1.9500 1.9500 6,220,200
May 31, 2022 2.6300 3.3500 2.1240 2.2200 2.2200 13,239,100
Apr 30, 2022 3.6800 4.0360 2.5500 2.5900 2.5900 9,053,400
Mar 31, 2022 6.1900 6.8000 3.5000 3.6600 3.6600 8,466,600
Mar 01, 2022 4.3900 6.6300 4.1600 6.1900 6.1900 11,176,500
Feb 01, 2022 6.1000 7.2800 3.7920 4.3500 4.3500 16,120,800
Jan 01, 2022 12.6200 13.7000 5.3100 6.0800 6.0800 25,090,900
Dec 01, 2021 13.0300 14.6900 10.7100 12.6200 12.6200 29,715,500
Oct 31, 2021 13.1500 18.6800 11.5400 13.0100 13.0100 58,732,900
Sep 30, 2021 91.5000 98.5000 12.4100 13.2000 13.2000 55,719,500
Aug 31, 2021 96.0400 101.7600 81.7000 91.6600 91.6600 4,687,000
Jul 31, 2021 57.1100 121.9800 55.3000 96.3000 96.3000 8,573,500
BRIEF-Quince Therapeutics Provides Pipeline Update And Business Outlook For 2023
Jan 30 (Reuters) - Quince Therapeutics Inc :
* QUINCE THERAPEUTICS PROVIDES PIPELINE UPDATE AND BUSINESS
OUTLOOK FOR 2023
* QUINCE THERAPEUTICS PROVIDES PIPELINE UPDATE AND BUSINESS
OUTLOOK FOR 2023
* QUINCE THERAPEUTICS - STRONG CASH POSITION OF
APPROXIMATELY $94
MILLION IN CASH, EQUIVALENTS, AND MARKETABLE SECURITIES AS OF
DECEMBER 31, 2022 and Potential for Quince to receive up to $150 million in regulatory and commercial milestones payments on a product-by-product basis, subject to conditions in the agreement
https://finance.yahoo.com/news/quince-therapeutics-completes-sale-legacy-130000851.html
* QUINCE THERAPEUTICS - CASH RUNWAY TO SUPPORT PIPELINE
EXPANSION
THROUGH IN-LICENSING AND ACQUISITION INTO AT LEAST 2028
Total Cash (mrq) 94.34M
Total Cash Per Share (mrq) 2.61
Total Debt (mrq) 420k
Shares Outstanding 36.13M
Float 27.6M
Quince Therapeutics, Inc. (QNCX) : 1.0000-0.0800 (-7.41%)
Jan 30 (Reuters) - Quince Therapeutics Inc :
* QUINCE THERAPEUTICS - ON JANUARY 24, BOARD OF COMPANY
APPROVED
COST REDUCTION PROGRAM TO ALIGN OPERATIONS WITH CHANGES IN
CORPORATE STRATEGY
* QUINCE THERAPEUTICS - UNDER PLAN, COMPANY IS REDUCING
HEADCOUNT
BY APPROXIMATELY 47% THROUGH A REDUCTION IN ITS WORKFORCE
* QUINCE THERAPEUTICS - REDUCTION IN FORCE WILL BEGIN IN
FEBRUARY
2023 AND WILL BE COMPLETED BY APRIL 2023
* QUINCE THERAPEUTICS - AS A RESULT, EXPECTS TO REALIZE
ESTIMATED
ANNUALIZED OPERATING EXPENSE SAVINGS OF ABOUT $9.5 MILLION IN
YEAR ENDING DEC 31, 2023
* QUINCE THERAPEUTICS - REDUCTION IN FORCE WILL BEGIN IN
FEBRUARY
2023 AND WILL BE COMPLETED BY APRIL 2023
* QUINCE THERAPEUTICS - EXPECTS TO REALIZE ESTIMATED
ANNUALIZED
OPERATING EXPENSE SAVINGS OF APPROXIMATELY $9.5 MILLION IN YEAR
ENDING DECEMBER 31, 2023
* QUINCE THERAPEUTICS - IN CONNECTION WITH PLAN, COMPANY
ESTIMATES
THAT IT WILL INCUR EXPENSES OF APPROXIMATELY $0.6 MILLION TO
$0.8 MILLION
Jan 01, 2023 0.6450 1.4700 0.6370 1.0800 1.0800 67,051,000
Dec 01, 2022 0.7490 0.7600 0.5400 0.6370 0.6370 5,975,600
Oct 31, 2022 1.0000 1.0390 0.6500 0.7370 0.7370 5,404,500
Sep 30, 2022 1.3700 1.3700 0.8620 1.0000 1.0000 3,903,500
Aug 31, 2022 1.7300 1.7580 1.2000 1.3300 1.3300 4,722,200
Jul 31, 2022 1.9700 2.7170 1.6500 1.7600 1.7600 5,607,500
Jun 30, 2022 2.2700 2.5800 1.7820 1.9500 1.9500 6,220,200
May 31, 2022 2.6300 3.3500 2.1240 2.2200 2.2200 13,239,100
Apr 30, 2022 3.6800 4.0360 2.5500 2.5900 2.5900 9,053,400
Mar 31, 2022 6.1900 6.8000 3.5000 3.6600 3.6600 8,466,600
Mar 01, 2022 4.3900 6.6300 4.1600 6.1900 6.1900 11,176,500
Feb 01, 2022 6.1000 7.2800 3.7920 4.3500 4.3500 16,120,800
Jan 01, 2022 12.6200 13.7000 5.3100 6.0800 6.0800 25,090,900
Dec 01, 2021 13.0300 14.6900 10.7100 12.6200 12.6200 29,715,500
Oct 31, 2021 13.1500 18.6800 11.5400 13.0100 13.0100 58,732,900
Sep 30, 2021 91.5000 98.5000 12.4100 13.2000 13.2000 55,719,500
Aug 31, 2021 96.0400 101.7600 81.7000 91.6600 91.6600 4,687,000
Jul 31, 2021 57.1100 121.9800 55.3000 96.3000 96.3000 8,573,500
BRIEF-Quince Therapeutics Provides Pipeline Update And Business Outlook For 2023
Jan 30 (Reuters) - Quince Therapeutics Inc :
* QUINCE THERAPEUTICS PROVIDES PIPELINE UPDATE AND BUSINESS
OUTLOOK FOR 2023
* QUINCE THERAPEUTICS PROVIDES PIPELINE UPDATE AND BUSINESS
OUTLOOK FOR 2023
* QUINCE THERAPEUTICS - STRONG CASH POSITION OF
APPROXIMATELY $94
MILLION IN CASH, EQUIVALENTS, AND MARKETABLE SECURITIES AS OF
DECEMBER 31, 2022 and Potential for Quince to receive up to $150 million in regulatory and commercial milestones payments on a product-by-product basis, subject to conditions in the agreement
https://finance.yahoo.com/news/quince-therapeutics-completes-sale-legacy-130000851.html
* QUINCE THERAPEUTICS - CASH RUNWAY TO SUPPORT PIPELINE
EXPANSION
THROUGH IN-LICENSING AND ACQUISITION INTO AT LEAST 2028
Total Cash (mrq) 94.34M
Total Cash Per Share (mrq) 2.61
Total Debt (mrq) 420k
Shares Outstanding 36.13M
Float 27.6M
Astrotech Corporation (ASTC) 12.00+0.23 (+1.95%)
https://www.astrotechcorp.com/_files/ugd/bac33b_384cbca1154e48d1a4093af8a8c2e442.pdf
Shares Outstanding 1.69M
Float 1.29M
Total Cash (mrq) 48.95M
Total Cash Per Share (mrq) 28.95
Total Debt (mrq) 480k
Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology. The company also develops TRACER 1000, a mass spectrometer-based explosive trace detector to replace the explosives trace detectors used at airports, cargo and other secured facilities, and borders. In addition, it develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. Further, the company develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 and is based in Austin, Texas.
Jan 01, 2023 9.99 12.34 9.99 11.83 11.83 111,100
Dec 01, 2022 9.90 11.82 9.28 9.99 9.99 546,417
Oct 31, 2022 12.00 13.50 9.30 10.20 10.20 301,281
Sep 30, 2022 13.20 13.80 10.20 12.30 12.30 183,265
Aug 31, 2022 13.80 14.40 12.30 13.20 13.20 204,439
Jul 31, 2022 13.80 16.20 12.30 13.80 13.80 263,144
Jun 30, 2022 12.60 14.70 12.60 13.80 13.80 63,550
May 31, 2022 16.50 17.10 12.60 12.90 12.90 107,050
Apr 30, 2022 15.90 16.80 14.40 16.50 16.50 98,090
Mar 31, 2022 21.60 22.20 15.90 16.20 16.20 121,183
Mar 01, 2022 21.60 23.10 19.80 21.60 21.60 192,625
Feb 01, 2022 19.20 22.20 18.00 21.30 21.30 249,151
Jan 01, 2022 20.40 23.10 18.00 19.50 19.50 234,297
Dec 01, 2021 24.30 24.60 19.50 20.40 20.40 371,402
Oct 31, 2021 31.20 33.00 22.80 24.00 24.00 522,731
Sep 30, 2021 31.50 34.50 29.10 30.90 30.90 726,944
Aug 31, 2021 33.30 33.90 28.80 31.50 31.50 391,866
Jul 31, 2021 34.50 36.30 28.20 33.30 33.30 1,657,386
Jun 30, 2021 41.40 42.00 30.00 32.40 32.40 963,596
May 31, 2021 35.40 39.90 33.60 39.90 39.90 1,113,366
Apr 30, 2021 36.90 37.20 30.90 35.10 35.10 998,583
Mar 31, 2021 66.60 89.40 32.10 36.90 36.90 6,113,055
Mar 01, 2021 70.50 76.20 42.90 65.70 65.70 1,323,382
Feb 01, 2021 59.40 124.20 59.40 65.70 65.70 2,390,276
Jan 01, 2021 53.10 79.50 51.90 61.20 61.20 924,834
Dec 01, 2020 58.50 63.30 50.40 53.10 53.10 537,875
Oct 31, 2020 58.50 59.70 47.40 58.50 58.50 498,903
Sep 30, 2020 51.90 184.20 46.80 59.70 59.70 6,190,508
Aug 31, 2020 64.50 76.50 43.20 51.00 51.00 1,010,051
Jul 31, 2020 92.40 108.90 63.30 65.70 65.70 140,379
Jun 30, 2020 86.10 110.10 76.20 92.40 92.40 305,287
May 31, 2020 78.90 101.10 76.80 85.50 85.50 207,531
Apr 30, 2020 90.00 109.80 76.50 80.40 80.40 263,573
Mar 31, 2020 73.20 126.00 65.40 89.10 89.10 624,170
Mar 01, 2020 49.80 232.50 29.40 78.00 78.00 2,294,158
Astrotech Corporation (ASTC) 12.00+0.23 (+1.95%)
https://www.astrotechcorp.com/_files/ugd/bac33b_384cbca1154e48d1a4093af8a8c2e442.pdf
Shares Outstanding 1.69M
Float 1.29M
Total Cash (mrq) 48.95M
Total Cash Per Share (mrq) 28.95
Total Debt (mrq) 480k
Astrotech Corporation operates as a mass spectrometry company worldwide. It owns and licenses the intellectual property related to the Astrotech Mass Spectrometer Technology, a platform mass spectrometry technology. The company also develops TRACER 1000, a mass spectrometer-based explosive trace detector to replace the explosives trace detectors used at airports, cargo and other secured facilities, and borders. In addition, it develops AgLAB-1000, a mass spectrometer for use in the hemp and cannabis market. Further, the company develops BreathTest-1000, a breath analysis tool to screen for volatile organic compound metabolites found in a person's breath. The company was formerly known as SPACEHAB, Inc. and changed its name to Astrotech Corporation in 2009. Astrotech Corporation was incorporated in 1984 and is based in Austin, Texas.
Jan 01, 2023 9.99 12.34 9.99 11.83 11.83 111,100
Dec 01, 2022 9.90 11.82 9.28 9.99 9.99 546,417
Oct 31, 2022 12.00 13.50 9.30 10.20 10.20 301,281
Sep 30, 2022 13.20 13.80 10.20 12.30 12.30 183,265
Aug 31, 2022 13.80 14.40 12.30 13.20 13.20 204,439
Jul 31, 2022 13.80 16.20 12.30 13.80 13.80 263,144
Jun 30, 2022 12.60 14.70 12.60 13.80 13.80 63,550
May 31, 2022 16.50 17.10 12.60 12.90 12.90 107,050
Apr 30, 2022 15.90 16.80 14.40 16.50 16.50 98,090
Mar 31, 2022 21.60 22.20 15.90 16.20 16.20 121,183
Mar 01, 2022 21.60 23.10 19.80 21.60 21.60 192,625
Feb 01, 2022 19.20 22.20 18.00 21.30 21.30 249,151
Jan 01, 2022 20.40 23.10 18.00 19.50 19.50 234,297
Dec 01, 2021 24.30 24.60 19.50 20.40 20.40 371,402
Oct 31, 2021 31.20 33.00 22.80 24.00 24.00 522,731
Sep 30, 2021 31.50 34.50 29.10 30.90 30.90 726,944
Aug 31, 2021 33.30 33.90 28.80 31.50 31.50 391,866
Jul 31, 2021 34.50 36.30 28.20 33.30 33.30 1,657,386
Jun 30, 2021 41.40 42.00 30.00 32.40 32.40 963,596
May 31, 2021 35.40 39.90 33.60 39.90 39.90 1,113,366
Apr 30, 2021 36.90 37.20 30.90 35.10 35.10 998,583
Mar 31, 2021 66.60 89.40 32.10 36.90 36.90 6,113,055
Mar 01, 2021 70.50 76.20 42.90 65.70 65.70 1,323,382
Feb 01, 2021 59.40 124.20 59.40 65.70 65.70 2,390,276
Jan 01, 2021 53.10 79.50 51.90 61.20 61.20 924,834
Dec 01, 2020 58.50 63.30 50.40 53.10 53.10 537,875
Oct 31, 2020 58.50 59.70 47.40 58.50 58.50 498,903
Sep 30, 2020 51.90 184.20 46.80 59.70 59.70 6,190,508
Aug 31, 2020 64.50 76.50 43.20 51.00 51.00 1,010,051
Jul 31, 2020 92.40 108.90 63.30 65.70 65.70 140,379
Jun 30, 2020 86.10 110.10 76.20 92.40 92.40 305,287
May 31, 2020 78.90 101.10 76.80 85.50 85.50 207,531
Apr 30, 2020 90.00 109.80 76.50 80.40 80.40 263,573
Mar 31, 2020 73.20 126.00 65.40 89.10 89.10 624,170
Mar 01, 2020 49.80 232.50 29.40 78.00 78.00 2,294,158
NOVA LIFESTYLE INC (NVFY) 0,94 +10,85%
Nova LifeStyle, Inc., through its subsidiaries, designs, manufactures, markets, and sells residential and commercial furniture for middle and upper middle-income consumers worldwide. The company offers upholstered, wood, and metal-based furniture pieces for the living, dining, and bedrooms, as well as home offices. Its products include sofas, chairs, dining and coffee tables, beds, entertainment consoles, cabinets, and cupboards. The company also provides physiotherapeutic jade mats for use in therapy clinic, hospitality, and real estate projects. It distributes its products under the Diamond Sofa brand directly, as well as through internet sales and online marketing campaigns, and participation in exhibitions and trade shows primarily to furniture distributors and retailers. The company was formerly known as Stevens Resources, Inc. Nova LifeStyle, Inc. was founded in 2003 and is headquartered in Commerce, California.
https://novalifestyle.com/
Shares Outstanding 6.95M
Float 4.17M
Jan 01, 2023 0.4600 0.9000 0.4400 0.8500 0.8500 472,700
Dec 01, 2022 0.5300 0.5900 0.3900 0.4300 0.4300 423,200
Oct 31, 2022 0.6100 0.6800 0.4700 0.5100 0.5100 303,100
Sep 30, 2022 0.7200 0.8100 0.5900 0.6000 0.6000 286,200
Aug 31, 2022 0.7600 0.8100 0.6800 0.7400 0.7400 474,900
Jul 31, 2022 0.7400 1.3400 0.7000 0.7500 0.7500 6,661,300
Jun 30, 2022 0.7600 0.8100 0.6800 0.7400 0.7400 252,900
May 31, 2022 0.7800 1.0300 0.6300 0.7200 0.7200 1,298,900
Apr 30, 2022 1.0700 1.1800 0.6300 0.7800 0.7800 625,200
Mar 31, 2022 1.5000 1.7900 1.0300 1.0600 1.0600 834,400
Mar 01, 2022 1.2900 1.5600 1.1400 1.5000 1.5000 1,246,800
Feb 01, 2022 1.5500 1.7900 1.2500 1.3200 1.3200 1,674,100
Jan 01, 2022 1.8600 1.9900 1.4700 1.6000 1.6000 1,167,400
Dec 01, 2021 1.9800 2.0800 1.7700 1.8700 1.8700 1,115,600
Oct 31, 2021 2.2800 2.4800 1.8700 1.9500 1.9500 1,774,900
Sep 30, 2021 2.2800 2.7100 2.1000 2.2700 2.2700 4,279,100
Aug 31, 2021 2.3300 2.4600 2.0800 2.2700 2.2700 3,544,800
Jul 31, 2021 2.2800 2.6000 1.9000 2.3700 2.3700 5,851,200
Jun 30, 2021 3.1400 6.6600 2.1000 2.2800 2.2800 56,231,500
May 31, 2021 3.0000 3.4100 2.7700 3.1400 3.1400 899,200
Apr 30, 2021 2.8100 3.5900 2.5200 2.9900 2.9900 1,329,900
Mar 31, 2021 3.3500 3.4400 2.6100 2.7300 2.7300 734,000
Mar 01, 2021 3.0100 7.4900 2.0400 3.2400 3.2400 45,086,500
NOVA LIFESTYLE INC (NVFY) 0,94 +10,85%
Nova LifeStyle, Inc., through its subsidiaries, designs, manufactures, markets, and sells residential and commercial furniture for middle and upper middle-income consumers worldwide. The company offers upholstered, wood, and metal-based furniture pieces for the living, dining, and bedrooms, as well as home offices. Its products include sofas, chairs, dining and coffee tables, beds, entertainment consoles, cabinets, and cupboards. The company also provides physiotherapeutic jade mats for use in therapy clinic, hospitality, and real estate projects. It distributes its products under the Diamond Sofa brand directly, as well as through internet sales and online marketing campaigns, and participation in exhibitions and trade shows primarily to furniture distributors and retailers. The company was formerly known as Stevens Resources, Inc. Nova LifeStyle, Inc. was founded in 2003 and is headquartered in Commerce, California.
https://novalifestyle.com/
Shares Outstanding 6.95M
Float 4.17M
Jan 01, 2023 0.4600 0.9000 0.4400 0.8500 0.8500 472,700
Dec 01, 2022 0.5300 0.5900 0.3900 0.4300 0.4300 423,200
Oct 31, 2022 0.6100 0.6800 0.4700 0.5100 0.5100 303,100
Sep 30, 2022 0.7200 0.8100 0.5900 0.6000 0.6000 286,200
Aug 31, 2022 0.7600 0.8100 0.6800 0.7400 0.7400 474,900
Jul 31, 2022 0.7400 1.3400 0.7000 0.7500 0.7500 6,661,300
Jun 30, 2022 0.7600 0.8100 0.6800 0.7400 0.7400 252,900
May 31, 2022 0.7800 1.0300 0.6300 0.7200 0.7200 1,298,900
Apr 30, 2022 1.0700 1.1800 0.6300 0.7800 0.7800 625,200
Mar 31, 2022 1.5000 1.7900 1.0300 1.0600 1.0600 834,400
Mar 01, 2022 1.2900 1.5600 1.1400 1.5000 1.5000 1,246,800
Feb 01, 2022 1.5500 1.7900 1.2500 1.3200 1.3200 1,674,100
Jan 01, 2022 1.8600 1.9900 1.4700 1.6000 1.6000 1,167,400
Dec 01, 2021 1.9800 2.0800 1.7700 1.8700 1.8700 1,115,600
Oct 31, 2021 2.2800 2.4800 1.8700 1.9500 1.9500 1,774,900
Sep 30, 2021 2.2800 2.7100 2.1000 2.2700 2.2700 4,279,100
Aug 31, 2021 2.3300 2.4600 2.0800 2.2700 2.2700 3,544,800
Jul 31, 2021 2.2800 2.6000 1.9000 2.3700 2.3700 5,851,200
Jun 30, 2021 3.1400 6.6600 2.1000 2.2800 2.2800 56,231,500
May 31, 2021 3.0000 3.4100 2.7700 3.1400 3.1400 899,200
Apr 30, 2021 2.8100 3.5900 2.5200 2.9900 2.9900 1,329,900
Mar 31, 2021 3.3500 3.4400 2.6100 2.7300 2.7300 734,000
Mar 01, 2021 3.0100 7.4900 2.0400 3.2400 3.2400 45,086,500
HBRM: 0.0003 + 100%
We are presently in advanced talks with two companies – one from the US and a second from South Korea that is well known in cosmetic and skin wellness industry for high quality biotechnological applications in skincare.
331.000.000 buys (last was 18.000.000 buy at 0.0003)
1.000.000 sells
HBRM: 0.0003 + 100%
We are presently in advanced talks with two companies – one from the US and a second from South Korea that is well known in cosmetic and skin wellness industry for high quality biotechnological applications in skincare.
331.000.000 buys (last was 18.000.000 buy at 0.0003)
1.000.000 sells
????????
QNCX: 0.8663-0.2137 (-19.79%) x 36.130.000 = 31.3 million, with 94 million cash and Potential for Quince to receive up to $150 million in regulatory and commercial milestones payments on a product-by-product basis, subject to conditions in the agreement
https://finance.yahoo.com/news/quince-therapeutics-completes-sale-legacy-130000851.html
????????
QNCX: 0.8663-0.2137 (-19.79%) x 36.130.000 = 31.3 million, with 94 million cash and Potential for Quince to receive up to $150 million in regulatory and commercial milestones payments on a product-by-product basis, subject to conditions in the agreement
https://finance.yahoo.com/news/quince-therapeutics-completes-sale-legacy-130000851.html
Time for a strong recovery
HBRM: 0.0003 + 100%
Volume: 313.794.650
https://www.otcmarkets.com/stock/HBRM/news/story?e&id=2432097
Time for a strong recovery
HBRM: 0.0003 + 100%
Volume: 313.794.650
https://www.otcmarkets.com/stock/HBRM/news/story?e&id=2432097
The CEO said they have evidence of illegal naked shorting on their stock and that investigations were taking place
Further, as a testament to my confidence that our trajectory is heading in the right direction, I have elected to receive almost all of my 2023 base salary in Aterian’s stock.”
Aterian (ATER) premarktet 1.79 +0.43 (+31.62%)
The CEO said they have evidence of illegal naked shorting on their stock and that investigations were taking place
We continue to believe we are on the path to achieving Adjusted EBITDA profitability in the second half of 2023. Further, as a testament to my confidence that our trajectory is heading in the right direction, I have elected to receive almost all of my 2023 base salary in Aterian’s stock.”
Aterian (ATER) premarktet 1.79 +0.43 (+31.62%)
The CEO said they have evidence of illegal naked shorting on their stock and that investigations were taking place
We continue to believe we are on the path to achieving Adjusted EBITDA profitability in the second half of 2023. Further, as a testament to my confidence that our trajectory is heading in the right direction, I have elected to receive almost all of my 2023 base salary in Aterian’s stock.”
Quince Therapeutics (QNCX) only 1.08?????
94.34 (current cash) + 150 ($150 million in regulatory and commercial milestones payments) - 0.420 (debt) = 243 million : 36.13 = $6.75/share
Shares Outstanding 36.13M
Float 27.6M
Total Cash (mrq) 94.34M
Total Debt (mrq) 420k
Quince to receive a 7.5% ownership stake of Lighthouse Common stock with anti-dilution through the first $10 million raised.
https://www.lighthousepharma.com/
They better buy back 20 – 30% of the shares or sell there complete pipeline and give $7.5 – $8 to every shareholder.
Quince Therapeutics (QNCX) only 1.08?????
94.34 (current cash) + 150 ($150 million in regulatory and commercial milestones payments) - 0.420 (debt) = 243 million : 36.13 = $6.75/share
Shares Outstanding 36.13M
Float 27.6M
Total Cash (mrq) 94.34M
Total Debt (mrq) 420k
Quince to receive a 7.5% ownership stake of Lighthouse Common stock with anti-dilution through the first $10 million raised.
https://www.lighthousepharma.com/
They better buy back 20 – 30% of the shares or sell there complete pipeline and give $7.5 – $8 to every shareholder.
Azerion Group N.V. (AZRN.AS) Amsterdam NL00150006Z9
3.48
52w: 3.34 - 10.388
Shares Outstanding 111.74M
Float 17.93M
Group-owned stock 34,23 %
Principion Holding B.V. 23,50 %
H.T.P. Investments B.V. 12,08 %
EFIC1 Group Coöperatie U.A. 7,45 %
Yerhan Erbas 3,66 %
https://www.azerion.com/investors-bc/
Azerion Group N.V. operates a digital entertainment and media platform worldwide. Its integrated platform provides technology solutions to automate the purchase and sale of digital advertising inventory for advertisers, publishers, and game creators, as well as to develop, publish, distribute, and operate online social and casual games, and digital content. The company was founded in 2014 and is headquartered in Schiphol-Rijk, the Netherlands. Azerion Group N.V. is a subsidiary of Principion Holding B.V.
Azerion Group N.V. (AZRN.AS) Amsterdam NL00150006Z9
3.48
52w: 3.34 - 10.388
Shares Outstanding 111.74M
Float 17.93M
Group-owned stock 34,23 %
Principion Holding B.V. 23,50 %
H.T.P. Investments B.V. 12,08 %
EFIC1 Group Coöperatie U.A. 7,45 %
Yerhan Erbas 3,66 %
https://www.azerion.com/investors-bc/
Azerion Group N.V. operates a digital entertainment and media platform worldwide. Its integrated platform provides technology solutions to automate the purchase and sale of digital advertising inventory for advertisers, publishers, and game creators, as well as to develop, publish, distribute, and operate online social and casual games, and digital content. The company was founded in 2014 and is headquartered in Schiphol-Rijk, the Netherlands. Azerion Group N.V. is a subsidiary of Principion Holding B.V.